X-linked Hypophosphatemia (XLH)

What is X-linked hypophosphatemia?

X-linked hypophosphatemia (XLH) is a rare genetic disorder that affects bone development and phosphate regulation in the body. It is the most common form of inherited rickets, causing bones to become soft and weak due to inadequate phosphate levels. XLH affects approximately 1 in 20,000 people worldwide, making it a rare but significant connective tissue disorder. The condition follows an X-linked dominant inheritance pattern, meaning it can affect both males and females, though males typically experience more severe symptoms.

Key statistics

Symptoms

Bone deformities, short stature, dental problems, bone pain, delayed tooth eruption, recurrent dental abscesses, muscle weakness, delayed walking.

The symptoms of XLH typically appear in early childhood and primarily affect bone development. The most recognizable sign is progressive bowing of the legs, particularly the knees, which becomes apparent as children begin to walk and bear weight. Short stature is nearly universal, often becoming evident by age 2-3 years. Dental complications are frequent and distinctive, including delayed tooth eruption, spontaneous dental abscesses without obvious decay, and poor tooth mineralization. Children may experience bone pain and muscle weakness, leading to a characteristic waddling gait. Delayed motor development, particularly in walking, is common. In adults, symptoms may include bone pain, osteomalacia (bone softening), pseudofractures, and continued dental problems. Some individuals develop hearing loss or spinal stenosis over time.

Causes and risk factors

XLH is caused by mutations in the PHEX gene located on the X chromosome. This gene normally produces an enzyme that helps regulate phosphate levels in the body by controlling fibroblast growth factor 23 (FGF23). When the PHEX gene is mutated, FGF23 levels become elevated, leading to excessive phosphate loss through the kidneys and reduced vitamin D activation. This results in chronically low phosphate levels in the blood, which impairs proper bone and tooth mineralization. The condition follows an X-linked dominant pattern, meaning only one copy of the mutated gene is needed to cause symptoms. Risk factors include having an affected parent, with a 50% chance of inheritance regardless of the child’s sex, though males typically have more severe manifestations due to having only one X chromosome.

Submit Your Paper

Prevention

As XLH is a genetic condition, it cannot be prevented through lifestyle modifications or environmental interventions. However, genetic counseling and testing play crucial roles in family planning decisions. Individuals with a family history of XLH can undergo genetic testing to determine if they carry the mutation. Prenatal testing is available for at-risk pregnancies, including chorionic villus sampling and amniocentesis. Preimplantation genetic diagnosis (PGD) may be an option for couples using in vitro fertilization. Early recognition and treatment can significantly improve outcomes, making genetic screening and family history evaluation important preventive measures against complications.

Complications

Without appropriate treatment, XLH can lead to severe and progressive complications affecting multiple body systems. Skeletal deformities may worsen over time, including severe bowing deformities of the legs, spinal abnormalities, and increased risk of fractures. Growth retardation typically results in significant short stature in adulthood. Dental complications can become extensive, including tooth loss, chronic infections, and the need for multiple dental procedures. Joint problems may develop, including arthritis and reduced mobility. Hearing loss affects approximately 60% of adults with XLH. Some individuals develop spinal stenosis, which can cause nerve compression and neurological symptoms. Kidney stones and nephrocalcinosis may occur, particularly if treatment is not properly monitored. The chronic nature of bone pain can significantly impact quality of life and may lead to depression or anxiety.

Diagnosis

Diagnosis of XLH requires a combination of clinical features, biochemical testing, and genetic analysis. Blood tests reveal the characteristic pattern of low or low-normal serum phosphate levels, elevated or inappropriately normal FGF23 levels, and low or normal 1,25-dihydroxyvitamin D levels despite low phosphate. Alkaline phosphatase is typically elevated, reflecting increased bone turnover. Parathyroid hormone (PTH) levels are usually normal. Urine tests show excessive phosphate wasting through the kidneys. Radiological imaging demonstrates classic rickets changes, including delayed ossification, coxa vara, bowing deformities, looser zones (pseudofractures), and osteomalacia in adults. Dental X-rays may reveal enlarged pulp chambers and root abnormalities. Genetic testing for PHEX gene mutations confirms the diagnosis and enables family screening. The diagnostic journey often involves multiple healthcare providers, as symptoms may initially be attributed to nutritional rickets or other growth disorders.

Treatment

Treatment for XLH has evolved significantly with the introduction of targeted therapies. The traditional approach involves oral phosphate supplements combined with active vitamin D analogues such as calcitriol or alfacalcidol. However, this conventional therapy requires multiple daily doses and frequent monitoring due to the risk of nephrocalcinosis and secondary hyperparathyroidism. A major breakthrough came with the approval of burosumab, a monoclonal antibody that targets FGF23, addressing the underlying cause of phosphate wasting. Burosumab is administered by subcutaneous injection every two weeks and has shown superior efficacy in healing rickets and improving growth compared to conventional therapy. Orthopedic interventions may be necessary for severe bone deformities, including osteotomies to correct bowing and guided growth procedures. Dental care requires specialized attention, with regular monitoring and prompt treatment of infections. Pain management may include physical therapy and appropriate analgesics.

Prognosis

The prognosis for individuals with XLH has improved significantly with modern treatment approaches, particularly with the introduction of burosumab. With appropriate treatment started early in childhood, many complications can be prevented or minimized. Growth outcomes have improved, though most individuals remain shorter than average. Bone deformities can be corrected or prevented with timely intervention. Life expectancy is generally normal, though quality of life may be affected by chronic symptoms and the need for ongoing medical care. Untreated or inadequately treated XLH leads to progressive skeletal deformities, severe short stature, and significant dental complications. Early diagnosis and treatment initiation are crucial factors in determining long-term outcomes. Regular monitoring and treatment adjustments throughout life are necessary to maintain optimal bone health and prevent complications.

Quality of life

Living with XLH requires ongoing attention to multiple aspects of daily life, but many individuals lead fulfilling lives with appropriate support and treatment. Regular exercise, particularly low-impact activities like swimming and cycling, can help maintain bone strength and muscle function while minimizing stress on affected joints. Dietary considerations include ensuring adequate calcium intake, though phosphate supplementation should only be done under medical supervision. Sleep quality may be affected by bone pain, requiring proper pain management strategies. Mental health support is important, as chronic conditions can impact emotional well-being. Many individuals with XLH successfully pursue education and careers, though accommodations may be helpful for physical limitations. Connecting with support groups and patient advocacy organizations can provide valuable emotional support and practical advice. Regular dental care and preventive measures are essential for maintaining oral health.

Pregnancy and fertility

XLH does not typically affect fertility in men or women. However, pregnancy requires specialized management due to the X-linked inheritance pattern and potential medication adjustments. Women with XLH should receive genetic counseling before conception to understand the 50% risk of passing the condition to each child. Phosphate and vitamin D metabolism may change during pregnancy, requiring dose adjustments of supplements. Burosumab use during pregnancy requires careful consideration, as limited data exists regarding safety. Traditional phosphate and vitamin D supplementation is generally considered safer during pregnancy. Calcium demands increase during pregnancy and breastfeeding, necessitating close monitoring. Prenatal genetic testing can determine if the fetus is affected, allowing for informed decision-making and early treatment planning if needed.

Children

Children with XLH require specialized pediatric care focused on optimizing growth and preventing complications. Early diagnosis and treatment initiation are crucial for achieving the best outcomes. Growth should be monitored regularly using condition-specific growth charts, as standard charts may not reflect typical growth patterns in XLH. Physical therapy may help with motor development and gait training. School accommodations may be necessary, including modified physical activities and potential academic support if hearing loss affects learning. Pain management strategies appropriate for children should be implemented. Dental care requires particular attention, with regular check-ups and preventive measures to avoid abscesses. Family education about the condition helps ensure proper medication adherence and recognition of complications. Psychological support may be beneficial for children struggling with their diagnosis or physical differences.

When to see a doctor

Immediate medical attention is needed for signs of severe complications, including sudden onset of severe bone pain, signs of kidney problems such as decreased urination or blood in urine, or symptoms of spinal cord compression including numbness, weakness, or bowel/bladder dysfunction. Routine care should be sought for worsening bone deformities, persistent or increasing bone pain, dental problems including abscesses or tooth pain, hearing changes, or concerns about growth and development in children. Regular follow-up appointments are essential for monitoring treatment effectiveness and adjusting medications. Any signs of medication side effects, including kidney stones or excessive calcium levels, warrant prompt medical evaluation. Parents should consult healthcare providers if children show delays in walking, unusual gait patterns, or dental problems.

Regional context

Limited specific data exists regarding XLH prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean countries. The condition’s prevalence is likely similar to global estimates of 1 in 20,000, though regional genetic variations may exist. Access to specialized treatments like burosumab may vary across different healthcare systems in these regions. Genetic testing availability and genetic counseling services may be limited in some areas, potentially affecting diagnosis and family planning decisions. Healthcare infrastructure for rare diseases varies significantly across the region. The Global Medical Journal welcomes contributions from healthcare providers and researchers in these regions to better understand regional patterns and improve care access for individuals with XLH.

Research and clinical trials

Current research focuses on improving treatment outcomes and developing new therapeutic approaches for XLH. Studies are evaluating optimal dosing strategies for burosumab across different age groups and investigating long-term outcomes. Research into combination therapies and alternative FGF23-targeting approaches is ongoing. Gene therapy approaches are being explored as potential future treatments. Clinical trials are examining the effects of treatment on hearing loss and other complications. Researchers are also investigating biomarkers to better monitor treatment response and predict outcomes. Patients and families can search for relevant clinical trials on ClinicalTrials.gov using terms like “X-linked hypophosphatemia,” “XLH,” or “burosumab.” Participation in research studies contributes to advancing understanding and treatment of this rare condition.

Frequently asked questions

Will my child with XLH be able to live a normal life?

With proper treatment and support, most children with XLH can lead fulfilling lives, attend regular school, and pursue their goals, though ongoing medical care and some accommodations may be necessary.

Is XLH the same as vitamin D deficiency rickets?

No, XLH is a genetic form of rickets caused by phosphate wasting, while nutritional rickets is caused by vitamin D or calcium deficiency. The treatments are different, making proper diagnosis crucial.

How often will my child need burosumab injections?

Burosumab is typically given as a subcutaneous injection every two weeks. The exact dose is calculated based on body weight and must be administered by a healthcare provider or trained caregiver.

Can adults with XLH benefit from treatment?

Yes, adults can benefit from treatment, particularly with burosumab, which has shown effectiveness in healing osteomalacia and reducing pain in adults with XLH.

Will having XLH affect my ability to have children?

XLH does not affect fertility, but genetic counseling is recommended since there’s a 50% chance of passing the condition to each child. Prenatal testing options are available.

Support and resources

• XLH Network – Primary patient advocacy organization providing education, support, and research funding
• National Organization for Rare Disorders (NORD) – Comprehensive rare disease information and patient support
• Orphanet – European database of rare diseases with detailed medical information
• EURORDIS – European organization representing rare disease patients
• World Health Organization (WHO) – Global health information and rare disease initiatives
• Genetic Alliance – Support for genetic conditions and family advocacy

Related conditions

• Autosomal Dominant Hypophosphatemic Rickets
• Autosomal Recessive Hypophosphatemic Rickets
• Tumor-Induced Osteomalacia
• Vitamin D-Dependent Rickets
• Osteogenesis Imperfecta

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.